Who can use Enasidenib(Idhifa)?

This section describes the specific medical condition that IDHIFA is approved to treat.

Approved Use

IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific mutation in the isocitrate dehydrogenase-2 (IDH2) gene. The presence of this mutation must be confirmed using an FDA-approved diagnostic test prior to initiating treatment. This defines a targeted patient population for whom the therapy is intended.